Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
1.845
+0.005 (0.27%)
Mar 23, 2026, 4:00 PM EDT - Market closed
CELZ Revenue
In the year 2025, Creative Medical Technology Holdings had annual revenue of $6.00K, down -45.45%. Creative Medical Technology Holdings had revenue of $3.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$6.00K
Revenue Growth
-45.45%
P/S Ratio
1,139.81
Revenue / Employee
$1,500
Employees
4
Market Cap
6.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.00K | -5.00K | -45.45% |
| Dec 31, 2024 | 11.00K | 2.00K | 22.22% |
| Dec 31, 2023 | 9.00K | -79.60K | -89.84% |
| Dec 31, 2022 | 88.60K | 846.00 | 0.96% |
| Dec 31, 2021 | 87.75K | -76.75K | -46.65% |
| Dec 31, 2020 | 164.50K | -1.00K | -0.60% |
| Dec 31, 2019 | 165.50K | 41.10K | 33.04% |
| Dec 31, 2018 | 124.40K | 119.60K | 2,491.67% |
| Dec 31, 2017 | 4.80K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 3.85M |
| Xenetic Biosciences | 2.98M |
| Cyclerion Therapeutics | 2.86M |
| Addex Therapeutics | 198.82K |
| Cardio Diagnostics Holdings | 14.83K |
| Alaunos Therapeutics | 6.00K |
CELZ News
- 2 months ago - Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain - GlobeNewsWire
- 2 months ago - Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative - GlobeNewsWire
- 3 months ago - Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point - GlobeNewsWire
- 3 months ago - Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201 - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Issues Letter to Shareholders - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs - GlobeNewsWire